-+ 0.00%
-+ 0.00%
-+ 0.00%

Collegium amends 8-K to add Corium Therapeutics audited financial statements

PUBT·06/30/2026 20:06:42
Listen to the news
Collegium amends 8-K to add Corium Therapeutics audited financial statements
  • Collegium filed an amended Form 8-K that adds audited consolidated financial statements for Corium Therapeutics Holdings for the year ended Dec. 31, 2025, following its agreement to acquire AZSTARYS.
  • The filing includes a going-concern warning, citing recurring operating losses, a net capital deficiency, and cash and cash equivalents of USD 13.89 million at year-end.
  • Corium reported net product sales of USD 113.57 million in 2025, up from USD 79.56 million in 2024.
  • Net loss narrowed to USD 42.39 million from USD 153.83 million.
  • Subsequent events disclosed include a definitive agreement for Collegium to buy AZSTARYS for USD 650 million in cash, with potential milestone payments of up to USD 135 million, with closing expected in the second quarter of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Collegium Pharmaceutical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-079323), on June 30, 2026, and is solely responsible for the information contained therein.